Project description
Accelerating the 'spread' of highly focused high-energy proton beams for cancer therapy
For more than 100 years, the detrimental effects of radiation on living cells have been successfully harnessed to kill cancer cells. Proton therapy relies on a focused beam of high-energy protons instead of X-rays. It has been particularly successful in treating solid tumours, with a significantly reduced risk of causing damage to surrounding healthy tissue. However, current systems are still very large and expensive, limiting application. The EU-funded LPT project is developing a novel proton therapy system that could bring proton therapy to the forefront of options for patients around the world. Based on a patented particle acceleration and beam delivery technique, it promises significant cost savings as well as reduced complexity and physical space.
Objective
Cancer is a global problem with 14.1 million new cases occurring annually and an expected increase of 68% by 2030.
Ensuring effective and safe treatment remains a significant challenge for healthcare organisations. Studies have shown
proton therapy to be effective in treating many types of tumours, including tumours of the prostate, brain, head and neck,
central nervous system, lung, and gastrointestinal system as well as cancers that cannot be removed completely by surgery.
Proton therapy is the most advanced type of external-beam radiation therapy that uses protons at high energy to destroy
cancer cells. Proton therapy is routinely used for cancer treatment however it is limited by the sheer size and expense of the
systems. There are currently only 66 operational proton therapy facilities in the world, addressing only 3-5% of clinical
demand.
LPT is developing a proton therapy system that overcomes the presented challenges, saving up to 50% space and reducing
costs by up to 75%. LPT applies a patented approach to particle acceleration and beam delivery, combining nanotechnology
with Nobel- Prizewinning ultra-high-intensity lasers and advanced magnetics. These technological breakthroughs
enable meaningful reduction
in the size, complexity and cost of proton therapy systems that will enable the widespread adoption of proton therapy both
across Europe and globally.
The technology is supported by the Horizon 2020, SME instrument. The LPT project aims to take the innovation to the next
level through the collaboration of strong industrial and academia players. Together, HIL applied medical, THALES
Optronique and INFN, will achieve fundamental milestones in the development of the commercial system, namely PT-100.
This system will be constructed based on the Alpha system (developed with the support of SME instrument), with a higher
repetition rate and proton flux to enable clinical use and wide market adoption.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine surgery
- engineering and technology nanotechnology
- medical and health sciences clinical medicine oncology
- natural sciences physical sciences optics laser physics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EC - Horizon 2020 Framework Programme
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
IA - Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-FTI-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
9139000 Jerusalem
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.